ProQR Therapeutics N.V. (PRQR)
NASDAQ: PRQR · Real-Time Price · USD
2.630
+0.040 (1.54%)
Dec 20, 2024, 4:00 PM EST - Market closed
ProQR Therapeutics Income Statement
Financials in millions EUR. Fiscal year is January - December.
Millions EUR. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | 2018 - 2014 |
|---|---|---|---|---|---|---|---|
Period Ending | Sep '24 Sep 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 | 2018 - 2014 |
| Operating Revenue | 17.88 | 6.51 | 3.59 | 1.34 | - | - | Upgrade
|
| Other Revenue | 0.5 | 0.08 | 0.77 | 1.04 | 1.03 | 1.93 | Upgrade
|
| Revenue | 18.39 | 6.59 | 4.36 | 2.38 | 1.03 | 1.93 | Upgrade
|
| Revenue Growth (YoY) | 306.68% | 51.27% | 83.31% | 131.10% | -46.77% | -65.40% | Upgrade
|
| Gross Profit | 18.39 | 6.59 | 4.36 | 2.38 | 1.03 | 1.93 | Upgrade
|
| Selling, General & Admin | 14.5 | 16.24 | 18.65 | 17.37 | 13.69 | 12.89 | Upgrade
|
| Research & Development | 33.48 | 25.15 | 50.87 | 42.22 | 38.14 | 46.49 | Upgrade
|
| Operating Expenses | 47.98 | 41.38 | 69.52 | 59.59 | 51.82 | 59.38 | Upgrade
|
| Operating Income | -29.59 | -34.79 | -65.16 | -57.21 | -50.79 | -57.45 | Upgrade
|
| Interest Expense | -1.2 | -1.2 | -5.13 | -3.41 | -2.04 | -1.08 | Upgrade
|
| Interest & Investment Income | 3.77 | 2.59 | 0.11 | 0.01 | 0.31 | 0.76 | Upgrade
|
| Earnings From Equity Investments | - | - | -0.01 | -0.22 | -0.32 | 0.43 | Upgrade
|
| Currency Exchange Gain (Loss) | -0.26 | -0.26 | 4.76 | 1.51 | -1.99 | 0.72 | Upgrade
|
| Other Non Operating Income (Expenses) | 0.21 | 0.95 | 2.71 | -1.88 | -0.08 | - | Upgrade
|
| EBT Excluding Unusual Items | -27.06 | -32.7 | -62.72 | -61.2 | -54.91 | -56.61 | Upgrade
|
| Gain (Loss) on Sale of Investments | - | - | - | 0.51 | - | - | Upgrade
|
| Gain (Loss) on Sale of Assets | 2.93 | 3.02 | - | - | - | - | Upgrade
|
| Other Unusual Items | - | 1.87 | -1.39 | - | 8.42 | - | Upgrade
|
| Pretax Income | -24.13 | -27.81 | -64.11 | -60.68 | -46.49 | -56.61 | Upgrade
|
| Income Tax Expense | -0.19 | -0.08 | 0.1 | 0.12 | 0.12 | 0.13 | Upgrade
|
| Earnings From Continuing Operations | -23.94 | -27.74 | -64.2 | -60.8 | -46.61 | -56.75 | Upgrade
|
| Minority Interest in Earnings | - | -0.38 | -0.22 | 0.06 | 0.05 | 0.27 | Upgrade
|
| Net Income | -23.94 | -28.12 | -64.42 | -60.74 | -46.57 | -56.48 | Upgrade
|
| Net Income to Common | -23.94 | -28.12 | -64.42 | -60.74 | -46.57 | -56.48 | Upgrade
|
| Shares Outstanding (Basic) | 82 | 81 | 72 | 64 | 50 | 41 | Upgrade
|
| Shares Outstanding (Diluted) | 82 | 81 | 72 | 64 | 50 | 41 | Upgrade
|
| Shares Change (YoY) | 3.44% | 13.08% | 11.62% | 28.21% | 21.99% | 20.51% | Upgrade
|
| EPS (Basic) | -0.29 | -0.35 | -0.90 | -0.95 | -0.93 | -1.38 | Upgrade
|
| EPS (Diluted) | -0.30 | -0.35 | -0.90 | -0.95 | -0.93 | -1.38 | Upgrade
|
| Free Cash Flow | -34.25 | 20.18 | -69.22 | -26.5 | -47.98 | -44.55 | Upgrade
|
| Free Cash Flow Per Share | -0.42 | 0.25 | -0.97 | -0.41 | -0.96 | -1.09 | Upgrade
|
| Gross Margin | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | Upgrade
|
| Operating Margin | -160.94% | -527.60% | -1494.82% | -2405.80% | -4935.96% | -2971.81% | Upgrade
|
| Profit Margin | -130.21% | -426.43% | -1477.95% | -2554.25% | -4525.27% | -2921.88% | Upgrade
|
| Free Cash Flow Margin | -186.30% | 305.99% | -1587.89% | -1114.21% | -4663.17% | -2304.71% | Upgrade
|
| EBITDA | -28.61 | -34.11 | -64.38 | -56.55 | -48.44 | -55.39 | Upgrade
|
| D&A For EBITDA | 0.99 | 0.68 | 0.78 | 0.66 | 2.36 | 2.05 | Upgrade
|
| EBIT | -29.59 | -34.79 | -65.16 | -57.21 | -50.79 | -57.45 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.